BORTEZOMIB MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• On July 30, 2024, the U.S. FDA approved daratumumab and hyaluronidase-fihj (DarzalexFaspro, Janssen Research & Development, LLC) in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation therapy in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplant (ASCT)
• In December 2023, Janssen-Cilag International NV announced new data at the 55th ASH Annual Meeting, highlighting VELCADE (bortezomib) as a key treatment for multiple myeloma. The data show that higher cumulative doses of VELCADE improve survival, significantly enhance response rates and slow disease progression when combined with dexamethasone, and are associated with low rates of cardiotoxicity.
• In November 2023, GSK plc announced positive results from the interim analysis of the DREAMM-7 phase III trial, which showed that belantamabmafodotin, combined with bortezomib and dexamethasone (BorDex), significantly extended progression-free survival (PFS) compared to daratumumab plus BorDex in patients with relapsed or refractory multiple myeloma. The trial also observed a strong trend toward improved overall survival (OS) with a nominal p-value < 0.0005, and follow-up for OS is ongoing.